Sarepta Therapeutics stock price target raised to $17 from $12 at TD Cowen

Published 29/07/2025, 16:34
Sarepta Therapeutics stock price target raised to $17 from $12 at TD Cowen

Investing.com - TD Cowen has raised its price target on Sarepta Therapeutics (NASDAQ:SRPT) to $17.00 from $12.00 while maintaining a Hold rating on the stock. According to InvestingPro data, the stock is currently trading near its Fair Value, though it has seen a significant decline of about 88% year-to-date.

The price target increase follows the FDA’s recommendation to remove the voluntary clinical hold on Elevidys for ambulatory Duchenne muscular dystrophy (DMD) patients.

Sarepta has indicated it will resume Elevidys shipments for ambulatory DMD patients imminently, according to TD Cowen’s analysis.

TD Cowen believes the FDA announcement positively impacts Sarepta’s near-term relationship with the regulatory agency and the DMD patient community.

The firm also notes the development should improve Sarepta’s liquidity position and ability to service its debt, factors that contributed to the increased sum-of-the-parts price target.

In other recent news, Sarepta Therapeutics has seen significant developments regarding its Elevidys treatment. The FDA has lifted its hold on the Elevidys treatment for ambulatory patients, which had been in place for about a week, following a safety review of an incident involving an 8-year-old patient in Brazil. This decision led to a notable surge in Sarepta’s stock, reflecting market optimism. Barclays (LON:BARC) responded by upgrading Sarepta’s stock rating from Underweight to Equalweight, raising the price target to $22.00. Meanwhile, Piper Sandler adjusted its price target to $15.00, maintaining a Neutral rating. BMO Capital also revised its price target for Sarepta to $50.00, citing the FDA’s decision as a key factor. However, H.C. Wainwright raised its price target to $5.00 but maintained a Sell rating, pointing to challenges in the Elevidys franchise. These updates highlight the varying analyst perspectives on Sarepta’s recent regulatory news.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.